Xavier González Farre
Xavier González Farre
MEDICAL ONCOLOGY SPECIALIST
See more specialists on
Barcelonabarcelona
en/medical-staff/oncologist
Dr. Xavier González Farre is a leading oncologist specializing in medical oncology , with a strong academic background that includes a degree in Medicine from the Universidad de Lleida. He currently practices as a specialist in medical oncology at the Hospital Universitario General de Catalunya, where he makes significant contributions to the advancement of oncological medicine. Among his most notable publications is the article "Comparison of ultrasound guided surgery and radio-guided occult lesions localization (ROLL) for nonpalpable breast cancer excision," published in the journal Gland Surg in September 2023. Furthermore, Dr. González Farre is an active member of the Grupo SOLTI de Investigación Clínica en Cáncer de Mama, reflecting his commitment to research and the development of new therapeutic strategies in the field of breast cancer. His professional and academic career positions him as a leading figure in his specialty, contributing to the advancement of oncology in Spain.
Key information
- Latest Publication:Challenging Endocrine Sensitivity of Hormone Receptor-Positive/HER2-Negative Advanced Breast Cancer with the Combination of Eribulin and Endocrine Therapy: The REVERT Study.
- Belongs to:Grupo SOLTI de Investigación Clínica en Cáncer de Mama
Professional Details
Hospital Universitari General de Catalunya
SPECIALIST PHYSICIAN MEDICAL ONCOLOGY
January 2024
Grupo SOLT de investigación en cáncer de mama
Medical Manager
May 2014
Hospital Universitari Quirón Dexeus
Specialist doctor
April 2014
Hospital Clinic de Barcelona
Specialist doctor
January 2009
Hospital Sant Joan de Deu
Specialist doctor
January 2008
Hospital de La Santa Creu I Sant Pau
Medical Oncology Resident
January 2004
Study
Bachelor of Medicine
Universidad de Lleida
2003
Specialized Healthcare Training
Medical Oncology
Another qualification
Research Proficiency
Another qualification
Healthcare Leadership Program
Another qualification
Certificado Good Clinical Practices in Clinical Investigation
Participation as a co-investigator in multiple clinical trials in different tumors
2003
Co-investigator in more than 30 clinical trials, phase I, observational and epidemiological studies in breast cancer
2009
Challenging Endocrine Sensitivity of Hormone Receptor-Positive/HER2-Negative Advanced Breast Cancer with the Combination of Eribulin and Endocrine Therapy: The REVERT Study.
Journal Article
Comparison of ultrasound guided surgery and radio-guided occult lesions localization (ROLL) for nonpalpable breast cancer excision.
Journal Article
Efficacy and Determinants of Response to HER Kinase Inhibition in HER2-Mutant Metastatic Breast Cancer.
Clinical Trial, Phase II, Journal Article, Multicenter Study, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Govt, Research Support, U.S. Govt, Non-P.H.S.
Importance of lateral chest x-ray
Article
Individualization of treatment strategies
Article
Inferencia of tumor evolution during chemotherapy by computational modeling and analysis of genetic and phenotypic cellular diversity
Article
New immunotherapies in advanced renal cancer
Article
Oncolytic viruses: A new immunotherapeutic approach for breast cancer treatment?
Journal Article, Review
Pegylated postomal doxorubicin in combination with epirubicin-phosphamide and trastuzumab in HER2-positive metastatic breast cancer patients: efficacy and cardiac safety from the GEICAN/2004-05 study
Article
Prognosis in women with breast cancer and private extra insurance coverage
Article
Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial.
Clinical Trial, Phase II, Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Govt
SOLTI-1503 PROMETEO TRIAL: combination of talimogene laherparepvec with atezolizumab in early breast cancer.
Journal Article
SOLTI-1904 ACROPOLI TRIAL: efficacy of spartalizumab monotherapy across tumor-types expressing high levels of PD1 mRNA.
Journal Article, Review
Substance P autocrine signaling contributes to present HER2 activation that drives malignant progression and drug resistance in breast cancer
Article
The Lang-HER study: clinical and molecular analysis of patients with HER2+ advanced breast cancer who become long-term survivors with trastuzumab-based therapy
Article
The Peony trial: adding evidence to pertuzumab use in non-metastatic breast cancer.
Editorial, Comment
Trastuzumab Deruxtecan in HER2-Positive Metastatic Breast Cancer Patients with Brain Metastases: A DESTINY-Breast01 Subgroup Analysis.
Journal Article
When Is Sentinel Node Biopsy Indicated in High-Risk Ductal Carcinoma in situ? Four Hundred Sixty-Eight Cases from Three Institutions.
Journal Article
Why we must treat HER2-positive patients with trastuzumab in first-line treatment
Article
Grupo SOLTI de Investigación Clínica en Cáncer de Mama
Grupo Español de Investigación en Cáncer de Mama
Societat Catalano-Balear dOncologia
Sociedad Española de Oncología Médica
Make an appointment with this professional
Vídeos de
Consulta el contenido multimedia de este profesional.
Hospitals
Book an appointment now at one of our hospitals.
Hospital Universitari General de Catalunya
Pedro i Pons, 1
08190 Sant Cugat del Vallés Barcelona
Articles on
Browse the latest articles on Tu canal de salud.
¿No tienes seguro de salud?
Con nuestros Planes de Salud Quirónsalud Connect tendrás un médico de medicina general todos los días las 24 horas. Y además gestor personal y medición facial de constantes vitales.